PAION to Present at UBS Global Life Sciences Conference in New York September 26, 2005
Posted on: Tuesday, 20 September 2005, 12:00 CDT
AACHEN, Germany, Sept. 20 /PRNewswire/ -- PAION (Frankfurt, Prime Standard: PA8) [PA8.DE] a biopharmaceutical company focusing on developing drugs for the indications stroke and other thrombotic diseases today reported that the company will be presenting at the UBS Global Life Sciences Conference in New York City, on September 26, 2005 at 12:00 PM local time in Ballroom A, at the Grand Hyatt. Presentation will be followed by a Breakout Session at the "Music Box" on the Conference Level. Dr. Wolfgang Sohngen, Chief Executive Officer of PAION, will give a review of the company and update the audience on current clinical and business developments.
The presentation will review highlights related to PAION's lead PIII product Desmoteplase (INN), Enecadin and Solulin.
The live audio webcast of the presentation will be available on the "Investors" section of the Company's website, http://www.paion.de/. This webcast will be archived and available on PAION's website after the event for a period of 30 days.
Desmoteplase, first in a new class of plasminogen activators, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat Desmodus rotundus. It possesses high fibrin selectivity, allowing it to dissolve a clot locally without affecting the blood coagulation system. This is believed to potentially reduce the risk of intracranial bleeding (a common risk when administering blood clot-dissolvers) as compared to less fibrin-specific plasminogen activators. Currently in Phase III, Desmoteplase was tested in two independent Phase II studies for the treatment of acute ischemic stroke up to 9 hours after onset of symptoms. It has received fast-track designation from the U.S. Food and Drug Administration for the indication of acute ischemic stroke.
About PAION
PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercializing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION intends to build an integrated portfolio of drugs by exploiting its core expertise in identifying compounds with potential in the treatment of stroke and other thrombotic diseases, licensing or otherwise acquiring these compounds and advancing them through the clinical development and regulatory approval process. Currently, PAION's activities are focused on the development of the three drugs Desmoteplase, Enecadin, and Solulin. PAION's most advanced drug candidate, Desmoteplase, has received fast-track designation from the U.S. Food and Drug Administration for the indication acute ischemic stroke. During the first half-year 2005, PAION employed on average 59 people. Since 11 February 2005, PAION is listed at the Frankfurt Stock Exchange (Prime Standard Official Market, Stock Symbol PA8, ISIN DE000A0B65S3). More information is available at http://www.paion.de/.
PAION
CONTACT: Dr. Peer Nils Schroeder, Investor Relations-Public Relations,PAION AG, +49-241-44-53-152, pn.schroeder@paion.de
Web site: http://www.paion.de/
Source: PRNewswire
Related Articles
- Diabetes Drugs Emerge As Top Force in Drug Spending Growth
- Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
- What Approaches Can Companies Use to Create Drugs With Disease-Modifying Effects and to Treat Early-Stage Disease?
- While Some Physicians Believe That Inhaled Corticosteroids Are Overused for the Treatment of Chronic Obstructive Pulmonary Disease, Majority Say the Drugs Help Treat the Disease
- The United States Accounted for 50% of the World's Alimentary/Metabolic Drugs Market in 2005
- Study Notes Jump in Drug Spending in 2005
- HIV Stands Out As a Highly Lucrative and Expanding Market for Diagnostics Because of the Close Integration of Diagnostics in Day-to-Day Disease Diagnosis, Management and Drug Selection
- China Reports Yunnan's "Achievements" in Anti-Drug Campaign in 2005
- Czech Cabinet Approves 2005-2006 Anti-Drug Policy
- Preliminary Phase IIb Study Showed Rituxan Improved Symptoms in Rheumatoid Arthritis Patients Who Failed One or More Disease-Modifying Anti-Rheumatic Drugs
 |
 |
User Comments (0)
RSS Feeds